This program is supported by an independent education grant from Pfizer. This education program is only available to healthcare professionals in the USA.
Credits: AMA PRA Category 1 Credits™ (0.25.00 hours)
Type of activity: Enduring material (On-demand)
Launch date: September 16th 2026
Expiration date: December 31st 2027
Estimated time to complete this activity: 15 minutes
Prefer to read instead? Read our Key Clinical Summary here.
This is Module 1 of a three-part on-demand series: Module 2 and Module 3.
Activity Description
Join expert Dr. Andrew Laccetti, MD, MS, for a practical, case-based exploration of how to implement guideline-concordant homologous recombination repair (HRR) testing workflows and apply PARP inhibitor evidence to treatment selection in metastatic prostate cancer. This session examines how to navigate the complementary roles of germline and somatic testing, troubleshoot common diagnostic barriers, interpret complex genomic reports, and coordinate multidisciplinary care to manage toxicities and improve patient outcomes.
Session Highlights
- Implement comprehensive homologous recombination repair (HRR) testing for all metastatic prostate cancer patients by integrating both germline and somatic testing modalities.
- Navigate the clinical strengths and limitations of using archival tissue, metastatic biopsies, and circulating tumor DNA (ctDNA) to ensure optimal genomic sampling.
- Interpret complex genomic testing reports to accurately identify actionable driver mutations, such as BRCA2, while avoiding unwarranted treatment based on variants of uncertain significance (VUS) or clonal hematopoiesis.
- Overcome common operational barriers in testing workflows and utilize multidisciplinary care coordination to effectively sequence PARP inhibitors and manage treatment-related toxicities.
Who Should Participate?
This program is designed for healthcare professionals directly involved in the diagnosis, targeted treatment, and longitudinal management of patients with metastatic prostate cancer (mPC), who seek to implement guideline-concordant genomic testing and multidisciplinary care into routine clinical practice.
- Oncology and Urology Practitioners (Academic and Community)
- Oncology Nurses
- Nurse Practitioners
- Physician Assistants
- Pharmacists
- Genetic Counselors
- Other Healthcare Professionals involved in the care and treatment of patients with mPC
Faculty
Dr Andrew Laccetti
Dr Andrew Laccetti is a Genitourinary Medical Oncologist at NYU Langone Health’s Perlmutter Cancer Center, specializing in prostate, kidney, bladder, and testicular cancers. His clinical and research interests focus particularly on prostate cancer across the disease spectrum, from localized to advanced metastatic disease. He is actively involved in clinical and health services research, investigating novel treatment strategies and approaches to improve quality of life. Dr Laccetti is also committed to advancing personalized, patient-centered cancer care and innovative remote-monitoring strategies to improve treatment outcomes and patient experience.
Continuing Education Information
Commercial support: This activity received monetary support through an independent education grant from Pfizer.
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
Disclosures
Dr Andrew Laccetti has disclosed financial relationships within the past 24 months with the following ineligible companies: Advisory Board Member: Bayer, Johnson& Johnson, Pfizer. Research Support: Bayer, JANUX, Johnson&Johnson, Novartis, Pfizer.
These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education.
Dr Laccetti does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which he has no financial relationships.
AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.
Activity Accreditation for Health Professions
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses & Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
System Requirements
Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.
Unapproved and/or off-label use disclosure
AffinityCE/MedAll requires CE faculty to disclose to the participants:
- When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
- Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
CME Inquiries
For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Participation Costs
There is no cost to participate in this program.
This continuing education activity is active starting September 16th 2026, and will expire on December 31st 2027..
Estimated time to complete this activity: 15 minutes.